Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.

Med (New York, N.Y.) - 13 Jun 2025

Getz Ted M, Bewersdorf Jan Philipp

Abstract excerpt

Resistance to isocitrate dehydrogenase (IDH) inhibitors poses a significant challenge in acute myeloid leukemia (AML), indicating a need for novel IDH inhibitors. Hu et al. report the results of a phase 1 study of the dual IDH1/2 inhibitor HMPL-306 in relapsed/refractory IDH-mutant AML.1 The study highlights its manageable safety profile and robust preliminary efficacy, suggesting that it may be a valuable AML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Drug Resistance, Neoplasm
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH1 gene

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Identifiers

PMID: 40516517
DOI: 10.1016/j.medj.2025.100600

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.PMID 40516517Read ↗

HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read ↗

Olutasidenib: First Approval.Semantic proximity Read ↗

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.Semantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.